Form D · Biotechnology
Willow Biosciences Inc.
Calgary, A0 · CIK 0001833096
Offering snapshot reported Nov 19, 2020 · SEC filing
- Reported sold
- $1.17M Offering amount: $1.17M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 29, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 19, 2020 | Initial | $1,168,596 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $333K
- Finders' fees
- $0
- Form D file number
- 021-381071
Source: Form D, filed Nov 19, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Donald Archibald | Director |
| Travis Doupe | Executive |
| Jerry Ericsson | Executive |
| Al Foreman | Director |
| Fotis Kalantzis | Director |
| Sadiq H. Lalani | Director |
| Trevor Peters | Director, Executive |
| Chris Savile | Executive |
| Mathias Schuetz | Executive |
| Peter Seufer Wasserthal | Director |
| Christopher Speed | Executive |
| Talkkari Troy | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
202, 1201 5 Th Street S.W.
Calgary, A0, T2R 0Y6
Calgary, A0, T2R 0Y6